Decrease in serum prolactin levels after intravenous administration of piribedil

P. Masturzo, A. Carolei, G. Murialdo

Research output: Contribution to journalArticle

Abstract

A study was carried out in 6 normal healthy volunteers to investigate the effect of piribedil (1.5 mg intravenously as a bolus) on serum prolactin levels. The results showed that there was a significant decrease in the levels at 180 minutes after administration. When the prolactin changes were compared with those obtained after oral administration of l-dopa (500 mg) or bromocryptine (2.5 mg) the maximal percentage reduction from baseline levels was greatest with bromocryptine and least with piribedil at the doses used.

Original languageEnglish
Pages (from-to)31-34
Number of pages4
JournalPharmatherapeutica
Volume2
Issue number1
Publication statusPublished - 1978

Fingerprint

Piribedil
Bromocriptine
Intravenous Administration
Prolactin
Healthy Volunteers
Dihydroxyphenylalanine
Serum
Oral Administration

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Masturzo, P., Carolei, A., & Murialdo, G. (1978). Decrease in serum prolactin levels after intravenous administration of piribedil. Pharmatherapeutica, 2(1), 31-34.

Decrease in serum prolactin levels after intravenous administration of piribedil. / Masturzo, P.; Carolei, A.; Murialdo, G.

In: Pharmatherapeutica, Vol. 2, No. 1, 1978, p. 31-34.

Research output: Contribution to journalArticle

Masturzo, P, Carolei, A & Murialdo, G 1978, 'Decrease in serum prolactin levels after intravenous administration of piribedil', Pharmatherapeutica, vol. 2, no. 1, pp. 31-34.
Masturzo, P. ; Carolei, A. ; Murialdo, G. / Decrease in serum prolactin levels after intravenous administration of piribedil. In: Pharmatherapeutica. 1978 ; Vol. 2, No. 1. pp. 31-34.
@article{1aa0538c72f94dc080751bb1156cbb34,
title = "Decrease in serum prolactin levels after intravenous administration of piribedil",
abstract = "A study was carried out in 6 normal healthy volunteers to investigate the effect of piribedil (1.5 mg intravenously as a bolus) on serum prolactin levels. The results showed that there was a significant decrease in the levels at 180 minutes after administration. When the prolactin changes were compared with those obtained after oral administration of l-dopa (500 mg) or bromocryptine (2.5 mg) the maximal percentage reduction from baseline levels was greatest with bromocryptine and least with piribedil at the doses used.",
author = "P. Masturzo and A. Carolei and G. Murialdo",
year = "1978",
language = "English",
volume = "2",
pages = "31--34",
journal = "Pharmatherapeutica",
issn = "0308-051X",
number = "1",

}

TY - JOUR

T1 - Decrease in serum prolactin levels after intravenous administration of piribedil

AU - Masturzo, P.

AU - Carolei, A.

AU - Murialdo, G.

PY - 1978

Y1 - 1978

N2 - A study was carried out in 6 normal healthy volunteers to investigate the effect of piribedil (1.5 mg intravenously as a bolus) on serum prolactin levels. The results showed that there was a significant decrease in the levels at 180 minutes after administration. When the prolactin changes were compared with those obtained after oral administration of l-dopa (500 mg) or bromocryptine (2.5 mg) the maximal percentage reduction from baseline levels was greatest with bromocryptine and least with piribedil at the doses used.

AB - A study was carried out in 6 normal healthy volunteers to investigate the effect of piribedil (1.5 mg intravenously as a bolus) on serum prolactin levels. The results showed that there was a significant decrease in the levels at 180 minutes after administration. When the prolactin changes were compared with those obtained after oral administration of l-dopa (500 mg) or bromocryptine (2.5 mg) the maximal percentage reduction from baseline levels was greatest with bromocryptine and least with piribedil at the doses used.

UR - http://www.scopus.com/inward/record.url?scp=0018103739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018103739&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0018103739

VL - 2

SP - 31

EP - 34

JO - Pharmatherapeutica

JF - Pharmatherapeutica

SN - 0308-051X

IS - 1

ER -